M-M-RVaxPro
measles, mumps and rubella vaccine (live)
Table of contents
Overview
This is a summary of the European public assessment report (EPAR) for M-M-RVaxPro. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use M-M-RVaxPro.
For practical information about using M-M-RVaxPro, patients should read the package leaflet or contact their doctor or pharmacist.
-
List item
M-M-RVaxPro : EPAR - Summary for the public (PDF/74.57 KB)
First published: 09/08/2006
Last updated: 29/05/2017 -
-
List item
M-M-RVaxPro : EPAR - Risk-management-plan summary (PDF/1.76 MB)
First published: 10/12/2019
Authorisation details
Product details | |
---|---|
Name |
M-M-RVaxPro
|
Agency product number |
EMEA/H/C/000604
|
Active substance |
|
International non-proprietary name (INN) or common name |
measles, mumps and rubella vaccine (live)
|
Therapeutic area (MeSH) |
|
Anatomical therapeutic chemical (ATC) code |
J07BD52
|
Publication details | |
---|---|
Marketing-authorisation holder |
Merck Sharp & Dohme B.V.
|
Revision |
30
|
Date of issue of marketing authorisation valid throughout the European Union |
05/05/2006
|
Contact address |
Waarderweg 39 |
Product information
08/07/2022 M-M-RVaxPro - EMEA/H/C/000604 - IA/0118/G
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Vaccines
Therapeutic indication
M-M-RVaxPro is indicated for simultaneous vaccination against measles, mumps, and rubella in individuals 12 months or older.
For use in measles outbreaks, or for post-exposure vaccination, or for use in previously unvaccinated children older than 12 months who are in contact with susceptible pregnant women, and persons likely to be susceptible to mumps and rubella.